News News

CONTACT:

Sirnaomics, Inc.
Michael Molyneaux MD MBA
Chief Medical Officer
michaelmolyneaux@sirnaomics.com

ICR Healthcare

Investors: Stephanie Carrington
Tel: +1 646 277 1282
Stephanie.Carrington@icrinc.com

Media: Mark Corbae
Tel: 203-682-8288
Email: Mark.Corbae@icrinc.com

Hx
October 25, 2019 Sirnaomics Leadership to Speak at 7th China Renaissance Healthcare and Life Sciences Summit

GAITHERSBURG, MD., Oct. 24, 2019 /PRNewswire/ — Sirnaomics Inc., a biopharmaceutical company engaged in the discovery and development of…

Patrick Lu
October 19, 2019 Sirnaomics’ President and CEO Patrick Lu Gives Keynote Address at the 7th RNAi China Conference

Sirnaomics Inc., a clinical-stage biopharmaceutical company engaged in the discovery and development of RNAi therapeutics against cancer…

Sirnaomics June 03 Preview
June 3, 2019 Sirnaomics Counts on New RNA Technology to Fuel Wide-Ranging Cancer & Fibrosis Pipeline

While some RNA technology companies are still exploring the accompanying science, Sirnaomics, based in Gaithersburg MD with subsidiaries in Suzhou and Guangzhou, China, has already established 10 pre-clinical and clinical RNA based programs focused on oncology and fibrosis.

Sirnaomics Allan S News
May 28, 2019 Sirnaomics Appoints Allan L. Shaw as Chief Financial Officer

Mr. Shaw is a highly regarded biopharmaceutical executive and board member with more than twenty years of financial and strategic leadership experience.

Sirnaomics News Placeholder 01
May 16, 2019 Sirnaomics Publishes Data for Lead Candidate STP705 in Cancer Model as 2019 ASCO Abstract

Sirnaomics announced the results showing STP705 inhibits the growth of HuCCt-1 (a human cholangiocarcinoma cell line) as a xenograft tumor in nude mice.

1 2 3 4 9